Meeting
2018 ASCO Annual Meeting
Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
Authors
Changhoon Yoo
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea
Changhoon Yoo , Jihoon Kang , Kyu-Pyo Kim , Ho Yeong Lim , Jee Hyun Kim , Myung Ah Lee , Tae-You Kim , Baek-Yeol Ryoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01942083
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4078)
DOI
10.1200/JCO.2018.36.15_suppl.4078
Abstract #
4078
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
First Author: Emilie Wang
Poster
2014 ASCO Annual Meeting
A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
First Author: Anthony B. El-Khoueiry
Poster
2014 Gastrointestinal Cancers Symposium
A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
First Author: Anthony B. El-Khoueiry
Poster
2013 Gastrointestinal Cancers Symposium
Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
First Author: Bert O'Neil